Veltassa

Drug - Veltassa™ (patiromer) [Relypsa, Inc.]

March 2016

Therapeutic area - Hyperkalemia

Approval criteria

Patient has a diagnosis of chronic hyperkalemia AND one of the following:
- Patient has tried and failed sodium polystyrene sulfonate OR
- Patient has a known hypersensitivity to sodium polystyrene sulfonate

Quantity limit

Maximum of one packet daily (34 packets per 34 days)

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411